非侵入性纤维化标志物在胆汁淤积性肝病中的应用。
Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases.
机构信息
Hepatology Department, Reference Center for Chronic Inflammatory Biliary Diseases (MIVB), French Network for Childhood and Adult Rare Liver Diseases (FILFOIE), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris (APHP), 184 rue du Faubourg Saint-Antoine, 75571, Paris Cedex 12, France; Inserm UMR_S938, Faculty of Medicine Pierre et Marie Curie, Saint-Antoine Site, Paris 6 University, 27 rue de Chaligny, Paris 75012, France.
出版信息
Clin Liver Dis. 2016 Feb;20(1):143-58. doi: 10.1016/j.cld.2015.08.013. Epub 2015 Oct 9.
Methods of liver fibrosis assessment have changed considerably in the last 20 years, and noninvasive markers now have been recognized as major first-line tools in the management of patients with chronic viral hepatitis infection. But what about the efficiency and utility of these surrogate indices for the more uncommon chronic cholestatic liver diseases, namely primary biliary cirrhosis and primary sclerosing cholangitis? This article provides clinicians with a global overview of what is currently known in the field. Both diagnostic and prognostic aspects of noninvasive markers of fibrosis in cholestatic liver diseases are presented and discussed.
在过去的 20 年中，肝纤维化评估方法发生了很大变化，非侵入性标志物现在已被公认为慢性病毒性肝炎感染患者管理的主要一线工具。但是，对于原发性胆汁性肝硬化和原发性硬化性胆管炎等更为罕见的慢性胆汁淤积性肝病，这些替代指标的效率和实用性如何呢？本文为临床医生提供了该领域目前已知情况的全面概述。本文介绍和讨论了胆汁淤积性肝病纤维化非侵入性标志物的诊断和预后方面。
Zotero 插件